Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) reached a new 52-week low during trading on Tuesday . The stock traded as low as $67.16 and last traded at $67.16, with a volume of 192 shares trading hands. The stock had previously closed at $75.60.
Wall Street Analyst Weigh In
A number of research analysts have weighed in on ZLDPF shares. Cantor Fitzgerald upgraded Zealand Pharma A/S to a "strong-buy" rating in a report on Tuesday, January 21st. William Blair upgraded shares of Zealand Pharma A/S from a "hold" rating to a "strong-buy" rating in a research report on Friday, March 7th.
View Our Latest Research Report on ZLDPF
Zealand Pharma A/S Stock Performance
The stock has a market cap of $4.40 billion, a price-to-earnings ratio of -26.25 and a beta of 0.81. The company has a debt-to-equity ratio of 0.03, a current ratio of 35.49 and a quick ratio of 35.49. The firm has a fifty day moving average of $90.69 and a 200 day moving average of $103.54.
Zealand Pharma A/S (OTCMKTS:ZLDPF - Get Free Report) last issued its earnings results on Thursday, February 20th. The company reported ($0.59) earnings per share (EPS) for the quarter, topping analysts' consensus estimates of ($0.78) by $0.19. Zealand Pharma A/S had a negative return on equity of 15.24% and a negative net margin of 1,725.03%. The business had revenue of $1.30 million during the quarter, compared to the consensus estimate of $28.11 million. As a group, sell-side analysts forecast that Zealand Pharma A/S will post -2.19 EPS for the current year.
About Zealand Pharma A/S
(
Get Free Report)
Zealand Pharma A/S, a biotechnology company, engages in the discovery, development, and commercialization of peptide-based medicines in Denmark. It has a portfolio of medicines focusing on gastrointestinal and metabolic diseases, and other specialty disease areas with unmet medical needs. The company offers Dasiglucagon, a single use syringe or autoinjector for the treatment of severe hypoglycemia; and Dasiglucagon bi-hormone artificial pancreas systems containing insulin and dasiglucagon.
Further Reading
Before you consider Zealand Pharma A/S, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Zealand Pharma A/S wasn't on the list.
While Zealand Pharma A/S currently has a Strong Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Looking for the next FAANG stock before everyone has heard about it? Enter your email address to see which stocks MarketBeat analysts think might become the next trillion dollar tech company.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
